ZA200502575B - Cell-based detection and differentiation of disease states - Google Patents

Cell-based detection and differentiation of disease states Download PDF

Info

Publication number
ZA200502575B
ZA200502575B ZA200502575A ZA200502575A ZA200502575B ZA 200502575 B ZA200502575 B ZA 200502575B ZA 200502575 A ZA200502575 A ZA 200502575A ZA 200502575 A ZA200502575 A ZA 200502575A ZA 200502575 B ZA200502575 B ZA 200502575B
Authority
ZA
South Africa
Prior art keywords
panel
probes
disease
cancer
markers
Prior art date
Application number
ZA200502575A
Other languages
English (en)
Inventor
Norman J Pressman
Kenneth S Hirsch
Original Assignee
Monogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monogen Inc filed Critical Monogen Inc
Publication of ZA200502575B publication Critical patent/ZA200502575B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ZA200502575A 2002-09-12 2005-03-30 Cell-based detection and differentiation of disease states ZA200502575B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/241,753 US20030190602A1 (en) 2001-03-12 2002-09-12 Cell-based detection and differentiation of disease states

Publications (1)

Publication Number Publication Date
ZA200502575B true ZA200502575B (en) 2006-10-25

Family

ID=31991242

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200502575A ZA200502575B (en) 2002-09-12 2005-03-30 Cell-based detection and differentiation of disease states

Country Status (9)

Country Link
US (1) US20030190602A1 (zh)
EP (1) EP1546709A4 (zh)
JP (1) JP2006509185A (zh)
KR (1) KR20060011817A (zh)
CN (1) CN1695057A (zh)
AU (1) AU2003267105A1 (zh)
CA (1) CA2498411A1 (zh)
WO (1) WO2004025251A2 (zh)
ZA (1) ZA200502575B (zh)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2361996B (en) * 1998-10-29 2004-05-12 Cell Works Inc Multiple marker characterization of single cells
US20040115692A1 (en) * 2000-04-03 2004-06-17 Cytyc Corporation Methods, compositions and apparatuses for detecting a target in a preservative solution
US7298877B1 (en) * 2001-11-20 2007-11-20 Icad, Inc. Information fusion with Bayes networks in computer-aided detection systems
WO2004029221A2 (en) 2002-09-27 2004-04-08 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
US7943294B2 (en) * 2004-07-30 2011-05-17 Hologic, Inc. Methods for detecting oncofetal fibronectin
US20090162839A1 (en) * 2004-08-31 2009-06-25 Board Of Regents, The University Of Texas System Diagnosis and prognosis of cancer based on telomere length as measured on cytological specimens
CA2584197A1 (en) * 2004-10-14 2006-04-27 Genentech, Inc. Cop1 molecules and uses thereof
WO2006084195A2 (en) * 2005-02-03 2006-08-10 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Personal assessment including familial risk analysis for personalized disease prevention plan
US20070196820A1 (en) 2005-04-05 2007-08-23 Ravi Kapur Devices and methods for enrichment and alteration of cells and other particles
ATE527542T1 (de) * 2005-04-27 2011-10-15 Siemens Medical Solutions Verfahren zur herstellung von abbildungssonden unter verwendung von click chemie
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
EP1930445B1 (en) * 2005-09-02 2010-03-31 Toray Industries, Inc. Kit and method for detection of urothelial cancer
CN102260742A (zh) * 2005-10-21 2011-11-30 基因信息股份有限公司 用于使生物标志产物水平与疾病相关联的方法和装置
US20070122041A1 (en) * 2005-11-29 2007-05-31 Baback Moghaddam Spectral method for sparse linear discriminant analysis
DE602007009645D1 (de) * 2006-02-16 2010-11-18 Ventana Med Syst Inc Reagenzien und verfahren für krebsprognose und pathologische einstufung
US20070207467A1 (en) * 2006-03-01 2007-09-06 Ming Xu Detection of lymph node metastasis from gastric carcinoma
US20090130108A1 (en) * 2006-03-21 2009-05-21 The Regents Of The University Of California N-Cadherin and Ly6 E: Targets for Cancer Diagnosis and Therapy
US20100278821A1 (en) * 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US20070281305A1 (en) * 2006-06-05 2007-12-06 Sean Wuxiong Cao Detection of lymph node metastasis from gastric carcinoma
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
WO2007147074A2 (en) 2006-06-14 2007-12-21 Living Microsystems, Inc. Use of highly parallel snp genotyping for fetal diagnosis
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
US8278056B2 (en) * 2008-06-13 2012-10-02 Oncohealth Corp. Detection of early stages and late stages HPV infection
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
WO2010129821A1 (en) 2009-05-07 2010-11-11 Oncohealth Corporation Identification of high grade or ≥cin2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (hpv) and hpv-associated cancers
US7824871B2 (en) * 2007-06-14 2010-11-02 George Mason Intellectual Properties Methods of diagnosing non-alcoholic steatohepatitis (NASH)
US8541183B2 (en) * 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
US7888051B2 (en) * 2007-09-11 2011-02-15 Cancer Prevention And Cure, Ltd. Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues
JP5378228B2 (ja) * 2007-10-29 2013-12-25 シスメックス株式会社 細胞分析装置及び細胞分析方法
US8617806B2 (en) * 2008-01-25 2013-12-31 Hansabiomed Ou Method to measure and characterize microvesicles in the human body fluids
AU2009210848B2 (en) * 2008-02-08 2013-12-19 Phadia Ab Method, computer program product and system for enabling clinical decision support
MX2010010835A (es) * 2008-04-04 2011-02-22 Univ California Novedosos anticuerpos contra cancer dirigidos a bloqueo de crecimiento de tumor, angiogenesis y metastasis.
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
CA3011730C (en) * 2008-09-09 2022-05-17 Somalogic, Inc. Lung cancer biomarkers and uses thereof
LT2562268T (lt) 2008-09-20 2017-04-25 The Board Of Trustees Of The Leland Stanford Junior University Neinvazinis fetalinės aneuploidijos diagnozavimas sekvenavimu
US8703920B2 (en) * 2008-11-10 2014-04-22 The Regents Of The University Of California Fully human antibodies against N-cadherin
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US8541170B2 (en) 2008-11-17 2013-09-24 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
FR2942319B1 (fr) * 2009-02-13 2011-03-18 Novacyt Procede de preparation d'une plaque d'analyse virtuelle traitee
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
EP3257953B1 (en) 2009-03-12 2018-09-26 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy
WO2010117711A1 (en) * 2009-03-29 2010-10-14 University Of Florida Research Foundation, Inc. Systems and methods for tuning automatic speech recognition systems
WO2010129934A2 (en) 2009-05-07 2010-11-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
TWI497075B (zh) * 2009-06-11 2015-08-21 Oncohealth Corp 早期及晚期人類乳突病毒感染之偵測
US8811535B2 (en) * 2009-07-17 2014-08-19 Mitre Corporation Time-frequency space constructions of families of signals
CA2781408A1 (en) * 2009-11-20 2011-05-26 University Of Louisville Research Foundation Inc. Biomarkers of cancer
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
EP2521914A4 (en) 2010-01-08 2013-07-10 Oncohealth Corp CELL-BASED HPV IMMUNOTESTS HAVE A HIGH PERFORMANCE FOR DIAGNOSIS AND SCANNING OF HPV ASSOCIATED CANCER
CN103038635B (zh) 2010-05-11 2016-12-28 威拉赛特公司 用于诊断病状的方法和组合物
US9514250B2 (en) * 2010-07-29 2016-12-06 General Electric Company System and method for analyzing and visualizing enumerated information
WO2012070970A1 (ru) * 2010-11-22 2012-05-31 Farber Boris Slavinovich Диагностический способ для прогноза развития и контроля эффективности лечения онкологических заболеваний
US20130029302A1 (en) * 2011-07-28 2013-01-31 Jill Joyce Psychiatric assessment by pre-screening and correlation of underlying physical conditions
US20130143237A1 (en) 2011-11-29 2013-06-06 Genentech, Inc. Compositions and methods for prostate cancer analysis
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
US10158898B2 (en) 2012-07-26 2018-12-18 Comcast Cable Communications, Llc Customized options for consumption of content
DK3435084T3 (da) 2012-08-16 2023-05-30 Mayo Found Medical Education & Res Prostatakræftprognose under anvendelse af biomarkører
GB2525804B (en) 2013-03-15 2020-08-05 Veracyte Inc Methods and compositions for classification of samples
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
EP2978863B1 (en) * 2013-03-28 2021-03-10 Advanced Cell Diagnostics, Inc. Differentiation between transient and persistent high risk hpv infection by in situ hybridization
WO2015010596A1 (zh) * 2013-07-22 2015-01-29 北京盛诺基医药科技有限公司 一种乳腺癌预后诊断的方法
DE102013015156B4 (de) * 2013-09-11 2016-10-20 Unify Gmbh & Co. Kg System und Verfahren zum Ermitteln des Präsenzstatus eines in einem Netzwerk registrierten Benutzers
US20160334389A1 (en) * 2014-01-14 2016-11-17 Won Cheol Choi Method for screening cancer prevention agent or anticancer agent using morphological characteristics of luterial
CA2951514A1 (en) 2014-06-18 2015-12-23 Clear Gene, Inc. Methods, compositions, and devices for rapid analysis of biological markers
EP3770274A1 (en) 2014-11-05 2021-01-27 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
US11401558B2 (en) 2015-12-18 2022-08-02 Clear Gene, Inc. Methods, compositions, kits and devices for rapid analysis of biological markers
CN107194137B (zh) * 2016-01-31 2023-05-23 北京万灵盘古科技有限公司 一种基于医疗数据建模的坏死性小肠结肠炎分类预测方法
CN106282116A (zh) * 2016-08-08 2017-01-04 北京科迅生物技术有限公司 一种结直肠癌循环肿瘤细胞的富集和分析方法
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
CN108133122B (zh) * 2016-12-01 2020-09-15 深圳华大基因股份有限公司 基因聚类方法和基于该方法的宏基因组组装方法和装置
US11208697B2 (en) 2017-01-20 2021-12-28 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
CN106919801B (zh) * 2017-03-08 2023-07-18 杭州大伽信息科技有限公司 一种免疫组织化学染色辅助分析系统及使用方法
US11873532B2 (en) 2017-03-09 2024-01-16 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018187496A2 (en) 2017-04-04 2018-10-11 Lung Cancer Proteomics, Llc Plasma based protein profiling for early stage lung cancer prognosis
WO2018205035A1 (en) 2017-05-12 2018-11-15 Genomedx Biosciences, Inc Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
US10327637B2 (en) * 2017-06-08 2019-06-25 Fdna Inc. Systems, methods, and computer-readable media for patient image analysis to identify new diseases
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
CN107367616B (zh) * 2017-07-27 2019-01-15 临沂大学 一种前列腺特异性抗原检测试剂与试剂盒
CN107475202A (zh) * 2017-08-18 2017-12-15 河南省肿瘤医院 一种肺癌循环肿瘤细胞捕获与活性检测、分析方法及其应用
US10939806B2 (en) * 2018-03-06 2021-03-09 Advinow, Inc. Systems and methods for optical medical instrument patient measurements
US11348688B2 (en) 2018-03-06 2022-05-31 Advinow, Inc. Systems and methods for audio medical instrument patient measurements
CA3136245A1 (en) * 2018-04-13 2019-10-17 Bioaffinity Technologies, Inc. System and method for determining lung health
CN108760448B (zh) * 2018-05-31 2024-08-16 广州江元医疗科技有限公司 全自动阴道分泌物染色机
US20210254173A1 (en) * 2018-06-15 2021-08-19 West Virginia University Predictive 7-gene assay and prognostic protein biomarker for non-small cell lung cancer
CN108846896A (zh) * 2018-06-29 2018-11-20 南华大学 一种自动分子蛋白质分子体学诊断系统
CN109554505B (zh) * 2018-12-26 2022-02-18 广东和信健康科技有限公司 一组检测hpv高危型和中危型核酸的探针及其检测试剂盒和应用
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
WO2020216437A1 (en) * 2019-04-23 2020-10-29 Espire Technologies Gmbh Device and method for localising or identifying malignancies
CN110376198B (zh) * 2019-08-29 2021-08-10 广州锟元方青医疗科技有限公司 一种宫颈液基细胞切片质量检测系统
US11795495B1 (en) * 2019-10-02 2023-10-24 FOXO Labs Inc. Machine learned epigenetic status estimator
CN111596059A (zh) * 2020-05-19 2020-08-28 上海长海医院 Gankyrin蛋白作为新型分子标志物在前列腺癌预后评估中的应用
US20230305014A1 (en) * 2020-08-11 2023-09-28 The Regents Of The University Of Michigan Methods of determining risk of and treating cancer recurrence
CN112002414B (zh) * 2020-08-23 2024-01-26 吾征智能技术(北京)有限公司 一种基于胃液认知胃病的系统、设备、存储介质
KR102577229B1 (ko) * 2021-05-25 2023-09-12 주식회사 에이치이엠파마 머신러닝 모델을 이용하여 복통 유무를 판별하는 방법 및 진단 장치
CN114638782B (zh) * 2022-01-10 2023-02-07 武汉中纪生物科技有限公司 一种宫颈脱落细胞标本的检测方法
WO2024090265A1 (ja) * 2022-10-28 2024-05-02 株式会社biomy 情報処理装置、情報処理方法及びプログラム

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
AU7357687A (en) * 1986-04-29 1987-11-24 Murex Corp. Diagnostic kit for sexually transmitted diseases
US4853770A (en) * 1988-03-01 1989-08-01 Joe Schneller Video system for viewing microscopic specimens
US5380645A (en) * 1989-03-16 1995-01-10 The Johns Hopkins University Generalized method for assessment of colorectal carcinoma
US5784162A (en) * 1993-08-18 1998-07-21 Applied Spectral Imaging Ltd. Spectral bio-imaging methods for biological research, medical diagnostics and therapy
US5543291A (en) * 1993-01-29 1996-08-06 Dana Farber Cancer Institute Method of detecting carcinoma
BR9404967A (pt) * 1993-04-14 1999-06-15 Int Murex Tech Corp Imunoensaio
WO1994028174A1 (en) * 1993-05-24 1994-12-08 Amoco Corporation Nucleic acid probes for bacteria of the genus legionella
IT1270951B (it) * 1993-06-07 1997-05-26 Boehringer Mannheim Italia Metodo e dispositivo per il rilevamento simultano di neisseria gonorrhoeae, chlamydia trachomatis e mycoplasma
US5895748A (en) * 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
NO308755B1 (no) * 1996-12-20 2000-10-23 Iystein Fodstad FremgangsmÕte til karakterisering av unormale celler, anvendelse og sett for utførelse av fremgangsmÕten
AU3316600A (en) * 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
GB0018140D0 (en) * 2000-07-24 2000-09-13 Medical Res Council Screening for abnormalities
US20030049701A1 (en) * 2000-09-29 2003-03-13 Muraca Patrick J. Oncology tissue microarrays
CN1554025A (zh) * 2001-03-12 2004-12-08 Īŵ���ɷ����޹�˾ 患病状态的细胞为基础的检测和鉴别
US7219016B2 (en) * 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues

Also Published As

Publication number Publication date
EP1546709A2 (en) 2005-06-29
CA2498411A1 (en) 2004-03-25
KR20060011817A (ko) 2006-02-03
WO2004025251A3 (en) 2004-11-04
JP2006509185A (ja) 2006-03-16
EP1546709A4 (en) 2007-09-26
WO2004025251A2 (en) 2004-03-25
AU2003267105A1 (en) 2004-04-30
US20030190602A1 (en) 2003-10-09
CN1695057A (zh) 2005-11-09

Similar Documents

Publication Publication Date Title
US6939670B2 (en) Cell-based detection and differentiation of lung cancer
ZA200502575B (en) Cell-based detection and differentiation of disease states
Yemelyanova et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases
Ferreira et al. Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients
US6746848B2 (en) Protein quantitation with cell imaging densitometry
US20140113310A9 (en) Cancer detection markers
Mhawech-Fauceglia et al. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma
Khoddami et al. Correlation between Gleason scores in needle biopsy and corresponding radical prostatectomy specimens: a twelve-year review
Huang et al. HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance
Connolly et al. Role of the Surgical Pathologist in the Diagnosis and Management of the Cancer Patient
Dalbagni et al. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder
Babu et al. Keratin 17 is a novel cytologic biomarker for urothelial carcinoma diagnosis
Gumus et al. Association of positive serum anti‐p53 antibodies with poor prognosis in bladder cancer patients
Zhang et al. Expression of proliferating cell nuclear antigen and CD44 variant exon 6 in primary tumors and corresponding lymph node metastases of colorectal carcinoma with Dukes' stage C or D
Kuhn et al. Soft tissue pathology for the radiologist: A tumor board primer with 2020 WHO classification update
Lou et al. Correlation of MTAP immunohistochemical deficiency with CDKN2A homozygous deletion and clinicopathological features in pleomorphic xanthoastrocytoma
Zhou et al. A prediction model for ROS1-rearranged lung adenocarcinomas based on histologic features
Kinoshita et al. Genomic‐based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma
Li et al. Automated and rapid detection of cancer in suspicious axillary lymph nodes in patients with breast cancer
Chung et al. Subjective differences in outcome are seen as a function of the immunohistochemical method used on a colorectal cancer tissue microarray
Morshed et al. An immunohistochemical study of cyclin D1 protein expression in laryngeal squamous cell carcinoma
Macluskey et al. An overview of the prevention of oral cancer and diagnostic markers of malignant change: 2. Markers of value in tumour diagnosis
Meng et al. Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens
Ennis et al. A comparison of E6H4 and G175-405 p16-specific monoclonal antibodies in oropharyngeal squamous cell carcinoma
Punjabi et al. Three shades of an unusual mediastinal tumour